Alkeus Pharmaceuticals
MA - CambridgePharmaceutical
Focus: Alkeus Pharmaceuticals is a pre-revenue biotech company focused on ophthalmology and neurology-adjacent indications, currently in Phase 3 development with a lead candidate in rare retinal disease.
Profile data last refreshed 2h ago · AI intelligence enriched 2mo ago
Employees
1-50
Total Funding
$1.5B
Open Jobs
3+2 this month
Stable — net +2 jobs in 30d
2 added, 0 removed. Backfill posture.
Should You Work at Alkeus Pharmaceuticals?
AI assessmentA high-risk, high-upside early-stage bet suited for career builders willing to exchange stability for outsized learning and potential equity appreciation.
Why Work Here
- Early-stage opportunity with Phase 3 lead program (ALK-001 in Stargardt Disease) offering visibility into near-term clinical catalysts and potential inflection points.
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
ALK-001
Stargardt DiseaseClinical Trials (5)
NCT07419334Study of ALK-001 on the Progression of Stargardt Disease
Phase 3Help build intelligence for Alkeus Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.